Germany's Merck KGaA raised its full-year guidance for growth in underlying earnings, thanks to better prospects for its life-sciences and healthcare segments, but turned more cautious on sales.

Germany's Merck KGaA on Thursday raised its full-year operating earnings guidance, excluding the effect of harsh foreign ...

During a Q2 earnings call, the firm discussed progress on an FGFR2b antibody, a subcutaneous version of Blincyto, and ...

The highest-paying dividend stocks in the Dow Jones Industrial Average right now are Verizon Communications (NYSE: VZ), ...

Pfizer beats Q2 2025 estimates, raises EPS guidance, boasts a 7%+ dividend yield, yet faces patent and pricing risks. See why ...

Donald Trump plans to impose new tariffs on pharmaceuticals and semiconductors to boost manufacturing in the US.

The number of biopharma professionals let go has increased year over year for three straight months. In July, nearly 8,000 ...

Merck KGaA closed the divestment of its global Surface Solutions business to Global New Material International Holdings Ltd. ...

MRK scores an A+ grade for Profitability, aided by high gross and EBITDA margins of 78% and 46%, respectively. Moreover, it ...

Gemini Insurance is under fire after a $2.5 million settlement claim, with Merck and Jones Lang LaSalle demanding coverage ...

Resting-state EEG (RS-EEG) has emerged as a non-invasive, low-cost tool for Alzheimer’s disease (AD) diagnosis and ...

Health-care company shares rose with the broader rebound in stocks as investors increasingly expect a rate cut from the Federal Reserve.